Drug Profile
Bevacizumab biosimilar - Shandong Boan Biotechnology
Alternative Names: BA-1101; Boyounuo; LY 01008Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer